Quantcast
Last updated on April 21, 2014 at 5:04 EDT

Latest Eisai Inc. Stories

2013-02-14 08:28:58

WOODCLIFF LAKE, N.J., Feb. 14, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the treatment,...

2013-02-04 08:26:38

EXTON, Pa., Feb. 4, 2013 /PRNewswire/ -- Morphotek(®) Inc., a subsidiary of Eisai Inc., announced today that its recently opened 60,000-square-foot pilot plant for the production of biological-based therapeutics to support early-stage clinical trials has been designated the 2013 Facility of the Year in the Sustainability category in a competition sponsored by the International Society for Pharmaceutical Engineering (ISPE), INTERPHEX, and Pharmaceutical Processing magazine. The...

2013-01-10 20:21:52

EXTON, Pa., Jan. 10, 2013 /PRNewswire/ -- Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study found that farletuzumab in combination with carboplatin and a taxane did not meet the study's primary endpoint of progression-free survival...

2012-12-17 12:24:04

WOODCLIFF LAKE, N.J. and ATLANTA, Dec. 17, 2012 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for Gliadel® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application (NDA) for Gliadel to Arbor,...

2012-12-11 08:27:39

WOODCLIFF LAKE, N.J., Dec. 11, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements for pediatric exclusivity for ACIPHEX(® )(rabreprazole sodium). As a result, Eisai has now gained an additional 6 months of United States market exclusivity for ACIPHEX, which will expire on November 8, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The granting of...

2012-11-30 08:24:39

WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex® Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age. (Logo:...

2012-11-28 12:26:49

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) These studies highlight Eisai's current and ongoing clinical research efforts with Halaven(®) (eribulin...

2012-11-19 08:29:16

WOODCLIFF LAKE, N.J., Nov. 19, 2012 /PRNewswire/ -- In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a donation of $100,000 to the Hurricane Sandy New Jersey Relief Fund as well as a $50,000 donation to the American Red Cross in an effort to help provide relief to the many areas damaged by Hurricane Sandy. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) "The devastation caused by Hurricane...

2012-11-12 08:28:33

EXTON, Pa., Nov. 12, 2012 /PRNewswire/ -- Morphotek(® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational cancer drug, amatuximab (MORAb-009) for the treatment of malignant pleural mesothelioma, the most common form of mesothelioma, which accounts for around 2,500 cases a year in the United States. This disease affects the pleura, which is the thin balloon shaped lining of...

2012-11-08 08:35:07

WOODCLIFF LAKE, N.J., Nov. 8, 2012 /PRNewswire/ -- With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome (LGS), many more may be struggling with the demands of caring for a loved one with this condition - a task that may require around-the-clock attention and support. In recognition of November as Epilepsy Awareness Month and the inaugural LGS Awareness Day on November 1, of which Eisai is a...